1. Angiopoietin-like protein 4 and cardiovascular function in COPD. Issue 1 (31st October 2016) Authors: Waschki, B; Kirsten, AM; Holz, O; Meyer, T; Lichtinghagen, R; Rabe, KF; Magnussen, H; Welte, T; Watz, H; Janciauskiene, S Journal: BMJ open respiratory research Issue: Volume 3:Issue 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B. (15th November 2016) Authors: Buhl, R; McGarvey, L; Korn, S; Ferguson, GT; Grönke, L; Hallmann, C; Voß, F; Rabe, KF; Maltais, F Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S102 Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. (12th November 2019) Authors: Calverley, PMA; Jenkins, C; Wedzicha, JA; de la Hoz, A; Voß, F; Rabe, KF; Anzueto, A Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S29 The impact of GOLD stage on the effectiveness of tiotropium/olodaterol in preventing COPD exacerbations in the DYNAGITO trial. (12th November 2019) Authors: Wedzicha, J; Calverley, PMA; Anzueto, AR; de la Hoz, A; Voß, F; Rabe, KF; Jenkins, C Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗